Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03288454 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

A Phase 2 study, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT03288454: Completed Phase 2 study, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.

NCT03288454 is a Phase 2 study that has completed, run by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03288454, a Phase 2 study, has completed, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).

Primary Outcome

Complete reversal is achieved if WBCT (manual method) is ≤ 110% of baseline at any post-baseline time point up to and including 1 hour following ciraparantag/PBO administration

Interventions

  • DRUG Placebo
  • DRUG Apixaban
  • DRUG Ciraparantag

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2017-08-30
Est. Completion 2019-08-05
Phase Phase 2
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals

9 total trials

What the finished NCT03288454 record still lists

NCT03288454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03288454 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03288454 about?

NCT03288454 is a clinical study titled "Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT". This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).

What is the current status of trial NCT03288454?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-08-30. Estimated completion is 2019-08-05.

What interventions are being tested in trial NCT03288454?

The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG), Ciraparantag (DRUG).

Who is sponsoring clinical trial NCT03288454?

This trial is sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT03288454's enrollment target sits among peer trials

60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03288454, the US trial registry maintained by the National Library of Medicine. NCT03288454 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.